Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Date:11/9/2007

are expected in the second half of 2008.

Pharmion recently initiated an international pivotal Phase 3 trial of Amrubicin versus topotecan as second-line treatment of small cell lung cancer (sensitive or refractory and limited or extensive disease). The randomized, controlled, multi-center study will compare Amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. The primary endpoint of the study is overall survival. Enrollment in the study of 480 patients is underway. Pharmion has completed the Scientific Advice (SA) process with the European Medicines Agency (EMEA) and has reached Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA) for the Amrubicin Phase 3 SCLC study.

About Amrubicin

Pharmion acquired the rights to Amrubicin in November 2006 through its acquisition of Cabrellis Pharmaceuticals. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of Amrubicin.

About Small Cell Lung Cancer

Small cell lung cancer is a disease in which malignant cells form in the tissues of the lung, and which occurs almost exclusively in people who smoke. While small cell lung cancer constitutes approximately 15 percent of all lung cancers, SCLC tends to be more aggressive and fast growing than the more common non-small cell lung cancer. Of the estimated 62,000 patients diagnosed with SCLC each year in the US and EU, approximately 60 percent of patients have extensive disease at diagnosis, and the remaining 40 percent present with localized, or limited stage, disease.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializi
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
7. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
8. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
9. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
(Date:7/10/2014)... New York City, NY (PRWEB) July 10, 2014 ... to the life sciences industry, has launched a new ... mobile responsiveness, as well as increased access to the ... “The new cbpartners.com provides an ideal platform to showcase ... global health access issues,” says CBPartners’ Chief Executive Officer, ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 ... the latest results of the 4th “Trending in ... suite model. , Every day multinational corporations ... contracts, expense forms etc. To meet this challenge, ... (S2P) suites which can be defined as a ...
(Date:7/10/2014)... -- Adults with dyslexia are more likely to report ... than people who don,t have the learning disorder, according ... up to 10 percent of people, causes problems with ... adults with this condition said they suffered physical abuse ... without dyslexia. "Even after accounting for age, race, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... the amount of alcoholic beverages consumed, even for ... reduced risk of coronary heart disease, lower body ... a new multi-center study published in The ... of Medicine at the University of Pennsylvania. The ... suggest that consuming light-to-moderate amounts of alcohol (0.6-0.8 ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:New study shows drinking alcohol provides no heart health benefit 2
... March 26 The statement below is attributable ... Association. This statement is being issued in response to ... England Journal of Medicine about prostate-specific antigen ... great interest the coverage surrounding the two studies about ...
... Percent of Surveyed MCO Pharmacy Directors Say They ... Idiopathic Arthritis and Pediatric Crohn,s Disease, According to ... 26 Decision Resources, one of the world,s ... healthcare issues, finds that 30 percent of surveyed ...
... radicals, researchers say , , THURSDAY, March 26 (HealthDay ... children,s lung growth and function, as well as ... University of Southern California researchers. , "Many factors ... variation and environmental exposures such as tobacco smoke ...
... (ASCTA) is formed in response to the Food and Drug Administration,s ... body are drugs, a position the ASCTA opposes. This physician ... adult stem cell therapy to their patients more quickly. , ... ...
... Strategic Cost Management Expertise with Hospitals Nationwide to Help ... An exclusive group of hospital CEOs from ... to Texas, and California to the Carolinas, will convene ... summit to address the implications of the economic stimulus ...
... March 26 Birner Dental Management Services, Inc. ... of PERFECT TEETH dental practices, ... Total dental group practice revenue decreased $371,000, or .6%, ... to $34.5 million. The Company,s earnings before interest, taxes, ...
Cached Medicine News:Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 2Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 3Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 2Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 3Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 3Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 2Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 2Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 4Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 5Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 6Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 7Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 8Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 9
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: